Parameter | Base case | Low | High | Distribution for PSA | Source |
---|---|---|---|---|---|
Cost estimates | |||||
Health care worker time cost | |||||
 Time nurses take to provide 1 dose IPTp-SP in Ghana (min) 95 % CI (N = 18) | 18.00 | 15.54 | 20.46 | Gamma | Observational study of trial participants: (Ghana) |
 Time nurses take to provide 1 dose IPTp-SP in Malawi (min) 95 % CI (N = 18) | 3.55 | 2.58 | 4.52 | Gamma | Observational study of trial participants: (Malawi) |
 Time nurses take to provide 1 admin ISTp-AL in Ghana (min) 95 % CI (N = 3) if RDT neg | 13.67 | 9.87 | 17.46 | Gamma | Observational study of trial participants: (Ghana) |
 Time nurses take to provide 1 admin ISTp-AL in Ghana (min) 95 % CI (N = 13) if RDT pos | 24.29 | 21.43 | 27.16 | Gamma | Observational study of trial participants: (Ghana) |
 Time nurses take to provide 1 admin ISTp-AL in Malawi (min) 95 % CI (N = 22) if RDT neg | 5.67 | 4.91 | 6.44 | Gamma | Observational study of trial participants: (Malawi) |
 Time nurses take to provide 1 admin ISTp-AL in Malawi (min) 95 % CI (N = 8) if RDT pos | 12.65 | 11.52 | 13.78 | Gamma | Observational study of trial participants: (Malawi) |
 Number of administrations in IPTp-SP arm | 2.06 | – | – | Point estimate | [20] |
 Number of administrations in ISTp-AL arm | 2.76 | – | – | Point estimate | [20] |
 % of administrations of ISTp with a positive RDT result | 24.7 % |  |  | Point estimate | [20] |
 Nurses’ monthly cost of labour, 95 % CI (US$ 2012) | 346.33 | 164.83 | 527.84 | Gamma | Countries MoHa |
Drug costs | |||||
 Average SP price per administration, 95 % CI (US$ 2012) | 0.20 | 0.16 | 0.27 | Lognormal | International procurement databasesb |
 Average AL price per administration, 95 % CI (US$ 2012) | 2.39 | 1.71 | 3.06 | Lognormal | International procurement databasesb |
 Average RDT price per administration, 95 % CI (US$ 2012) | 0.81 | 0.58 | 0.90 | Lognormal | International procurement databasesb |
Costs from consequences | |||||
 Incremental days in hospital comparing LBW versus NBW (days) | 0.64 | 0.40 | 0.89 | Normal | Trial post partum follow up data |
 Cost per paediatric IP day (excluding medical supplies) (US$ 2012) | 63.46 | 31.73 | 95.19 | Gamma | Health facility costings (Ghana, Mali) |
 Cost per OP visit (excluding medical supplies) (US$ 2012) | 11.76 | 8.45 | 15.06 | Gamma | Health facility costings (Ghana, Mali) |
 Cost per IP day (excluding medical supplies) (US$ 2012) | 35.25 | 17.63 | 52.88 | Gamma | Health facility costings (Ghana, Mali) |
Daly calculations | |||||
 Discount rate r | 0.03 | 0.00 | 0.05 | Point estimate | Assumption |
 Average age (years)c | 20.40 | – | – | Point estimate | [20] |
 Life expectancy women aged 20–24 years | 50.12 | 45.11 | 55.13 | Lognormal | GBD study 2010d [32] |
 Life expectancy at birth | 61.56 | 56.86 | 66.31 | Lognormal | GBD study 2010d [32] |
 Length disability—malaria during pregnancy (3.5 days, range 2–6) | 0.010 | 0.005 | 0.016 | Gamma | Assumption |
 Length disability—malaria related anaemia (21 days, range 14–42) | 0.06 | 0.04 | 0.12 | Gamma | Price et al. [33] |
 Length disability—LBW (years) | 57.96 | 52.91 | 64.80 | Lognormal | GBD 2010 study [32] |
 Disability weight infectious disease severe acute episode (95 % CI) | 0.21 | 0.14 | 0.30 | Lognormal | GBD 2010 study [25] |
 Disability weight maternal anaemia: moderate (95 % CI) | 0.06 | 0.04 | 0.09 | Lognormal | GBD 2010 study [25] |
 Disability weight LBW | 0.11 | – | – | Point estimate | GBD 2004 update (data from 1990) [26] |
Mortality estimates | |||||
 LBW attributable neonatal mortality risk % | 6.93 | 4.36 | 9.50 | Beta | Marchant et al. [34] |
 CFR malaria during pregnancy % | 0.0033 | 0.0026 | 0.0045 | Beta | Sicuri et al. [35] |
 CFR moderate/severe anaemia in pregnancy % | 0.01 | – | – | Beta | Brabin et al. [36] |
Measures of effect (trial conducted in Primi- and secundigravidae only) | |||||
Low birth weight | |||||
 LBW risk IPTp-SP arm per 1000 women | 151.2 | 136.8 | 166.8 | Beta | [20] |
 LBW risk ISTp-AL arm per 1000 women | 155.8 | 141.3 | 171.5 | Beta | [20] |
Moderate/severe maternal anaemia (<8, 7, or 6Â g/dl) | |||||
 Moderate/severe anaemia risk at last ANC visit IPTp-SP arm per 1000 women | 16.9 | 11.6 | 24.7 | Beta | [20] |
 Moderate/severe anaemia risk at last ANC visit ISTp-AL arm per 1000 women | 23.1 | 16.8 | 31.7 | Beta | [20] |
Episodes of clinical malaria | |||||
 0 episode clinical malaria IPTp-SP arm per 1000 women | 932.41 | 922.26 | 941.33 | Dirichlet | [20] |
 1 episode clinical malaria IPTp-SP arm per 1000 women | 61.99 | 53.45 | 71.78 | Dirichlet | [20] |
 2 episodes clinical malaria IPTp-SP arm per 1000 women | 5.6 | 3.38 | 9.27 | Dirichlet | [20] |
 3 episodes clinical malaria IPTp-SP arm per 1000 women | 0.4 | 0.36 | 0.44 | Dirichlet | [20] |
 0 episode clinical malaria ISTp-AL arm per 1000 women | 899.85 | 887.88 | 910.67 | Dirichlet | [20] |
 1 episode clinical malaria ISTp-AL arm per 1000 women | 84.08 | 74.14 | 95.21 | Dirichlet | [20] |
 2 episodes clinical malaria ISTp-AL arm per 1000 women | 14.95 | 10.98 | 20.32 | Dirichlet | [20] |
 3 episodes clinical malaria ISTp-AL arm per 1000 women | 0.37 | 0.05 | 2.65 | Dirichlet | [20] |
Measures of effect from cochrane review used for modelling of decreasing SP efficacy in IPTp arm | |||||
 Relative risk of LBW comparing IPTp-SP versus none or placebo | 0.81 | 0.67 | 0.99 | n/a | [30] |
 Relative risk of sev/mod anaemia comparing IPTp-SP versus none or placebo | 0.60 | 0.47 | 0.75 | n/a | [30] |
 Relative risk of antenatal parasitaemia comparing IPTp-SP versus none or placebo | 0.38 | 0.24 | 0.59 | n/a | [30] |